BMJ Global Health (Jan 2024)

A hybrid effectiveness-implementation trial of application-based tiered care (Mom’s Good Mood) in treating perinatal anxiety within a primary health care system in China

  • Yue Gu,
  • Fangbiao Tao,
  • Beibei Zhu,
  • Haiyan Li,
  • Mengjuan Lu,
  • Minmin Jiang,
  • Yanyan Hou,
  • Xiayan Yu,
  • Mengqing Shang,
  • Hualong Zhen

DOI
https://doi.org/10.1136/bmjgh-2023-013604
Journal volume & issue
Vol. 9, no. 1

Abstract

Read online

Introduction Perinatal anxiety (PNA) is a major public health concern.Methods A hybrid effectiveness-implementation trial was conducted in two antenatal clinics in Hefei, China, to assess the effectiveness and cost-effectiveness of application-based tiered care (Mom’s Good Mood, MGM) in treating PNA and to understand how well it fits into routine practices. Pregnant women who scored at least 5 points on the 7-Item Generalised Anxiety Disorder Scale (GAD-7) scale were successively assigned to the control group or the intervention group, which were given the usual care and MGM on usual care, respectively. At 6 months post partum, anxiety, depression and life satisfaction were assessed. Intention-to-treat analysis and the Reach, Effectiveness, Adoption, Implementation and Maintenance framework were adopted.Results A total of 214 women were assigned to the control group and 341 to the intervention group. The mean changes in GAD-7 scores (Least-squares means, LSM, −1.42, 95% CI −2.18 to −0.66) and the risk of anxiety (adjusted odds ratio, aOR 0.30, 95% CI 0.18 to 0.51) were decreased, and the anxiety remission rate (aOR 2.72, 95% CI 1.69 to 4.40) were improved in the intervention group. Similar findings were observed regarding the change in Edinburgh Postnatal Depression Scale scores (LS −1.92, 95% CI −2.85 to −0.99), depression remission rate (aOR 2.24, 95% CI 1.39 to 3.63) and the risk of depression (aOR 0.57, 95% CI 0.33 to 0.98). MGM only costs ¥1.88 (US$0.27) per pregnant woman to boost the postpartum anxiety remission rate by 1% and was revealed to have a high reach rate of 78.3%, an adoption rate of 51.3%–80.8%.Conclusion MGM is a cost-effective and accessible tool in coping with PNA.Trial registration number ChiCTR2100053419.